Xintela AB (publ) Stock price Nasdaq Stockholm
Equities
SE0007756903
Biotechnology & Medical Research
Sales 2021 | - | Sales 2022 | - | Capitalization | 151M 14.14M |
---|---|---|---|---|---|
Net income 2021 | -59M -5.54M | Net income 2022 | -66M -6.2M | EV / Sales 2021 | - |
Net cash position 2021 | 11.14M 1.05M | Net cash position 2022 | 8.34M 784K | EV / Sales 2022 | - |
P/E ratio 2021 |
-3.19
x | P/E ratio 2022 |
-1.33
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 31.28% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 67 | 08-12-31 | |
Gunnar Telhammar
DFI | Director of Finance/CFO | 63 | 12-12-31 |
Thomas Areschoug
PRN | Corporate Officer/Principal | 52 | 17-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lars Olof Hedbys
BRD | Director/Board Member | 67 | 20-12-31 |
Chairman | 67 | 10-12-31 | |
Thomas Eldered
BRD | Director/Board Member | 64 | - |
1st Jan change | Capi. | |
---|---|---|
+9.05% | 45.97B | |
+52.90% | 43.93B | |
+9.66% | 42.34B | |
-8.59% | 28.27B | |
+17.68% | 27.18B | |
-20.30% | 19.44B | |
+13.88% | 13.83B | |
+31.43% | 12.4B | |
+8.79% | 11.45B |